CLEC12A and breast carcinoma: While CLEC12A is primarily associated with leukemia, it has also been shown to sensitize breast cancer cells to artemisinin treatment by suppressing autophagy and inflammation (Chatterjee and Chatterji, 2022; Chatterjee et al., 2023).